Ask My Investor AI
Public company · listing under verificationPublished company research
HOLX

Identity taken from the accepted research seed; independent verification against official issuer and exchange sources is pending.

Hologic

Hologic is mapped to the Women's health formalization theme as Women's diagnostics and imaging - mammography/breast health, GYN surgical, and molecular diagnostics (cervical cytology and HPV).. High and directly on-theme. Fiscal Q2 2025 (ended 2025-03-29) shows Breast Health USD 356.2 million (-7.4% YoY on mammography capital softness), GYN Surgical USD 162.5 million (+4.2%), and Diagnostics USD 453.6 million (+0.8%, including ThinPrep cervical cytology and Aptima HPV). The large majority of Hologic's revenue is women's-health oriented. Theme materiality is stated separately and, where not independently verified, is marked accordingly.

Ask follow-up research
Reviewed company research · researched 2026-07-22 · not an individual investment recommendation
Listing
public
Ticker
HOLX
Exchange
None
HQ
—
Currency
n/a
SEC CIK
Non-SEC filer
Investment case

How this company captures the theme economics

Competitive position

High and directly on-theme. Fiscal Q2 2025 (ended 2025-03-29) shows Breast Health USD 356.2 million (-7.4% YoY on mammography capital softness), GYN Surgical USD 162.5 million (+4.2%), and Diagnostics USD 453.6 million (+0.8%, including ThinPrep cervical cytology and Aptima HPV). The large majority of Hologic's revenue is women's-health oriented. Company-specific competitive positioning is assessed at the theme level and awaits deeper primary research.

Scarce assets

Scarce assets in this value chain include reimbursement and coverage decisions (state ivf/fertility mandates, employer benefit design, cms/medicaid) - the gating variable for the whole theme., specialist capacity: reproductive endocrinologists/fertility clinics, urogynecology, maternal-fetal medicine., proprietary clinical data and validated assays/algorithms (nipt content, hpv assays, ai mammography)..

Products, segments, and customers

Hologic operates in Women's health formalization. Segment- and product-level detail is pending company-specific research.

Theme capture

High and directly on-theme. Fiscal Q2 2025 (ended 2025-03-29) shows Breast Health USD 356.2 million (-7.4% YoY on mammography capital softness), GYN Surgical USD 162.5 million (+4.2%), and Diagnostics USD 453.6 million (+0.8%, including ThinPrep cervical cytology and Aptima HPV). The large majority of Hologic's revenue is women's-health oriented.

Conditions

What must be true

  1. FY2025 10-K segment detail; ThinPrep/Aptima volumes and ASPs; Genius AI/3D mammography adoption and the breast-health capital replacement cycle.
  2. The exposure described for Hologic must be confirmed as financially material in official filings.

Identifiable catalysts

  • Forthcoming quarterly and annual issuer filings
  • Theme-level catalysts detailed in the Women's health formalization brief
Theme materiality

1 mapped theme

Exposure statements are evidence-qualified. Materiality is only claimed where disclosure supports it.

Women's diagnostics and imaging - mammography/breast health, GYN surgical, and molecular diagnostics (cervical cytology and HPV).

Women's health formalization

High and directly on-theme. Fiscal Q2 2025 (ended 2025-03-29) shows Breast Health USD 356.2 million (-7.4% YoY on mammography capital softness), GYN Surgical USD 162.5 million (+4.2%), and Diagnostics USD 453.6 million (+0.8%, including ThinPrep cervical cytology and Aptima HPV). The large majority of Hologic's revenue is women's-health oriented.

Evidence
Fetched Hologic fiscal Q2 2025 press release with divisional revenue and growth. Segment-level women's-health disclosure is explicit; capital-equipment cyclicality in Breast Health is a documented near-term drag.
Materiality
disclosed — Company discloses division-level revenue (Breast Health, GYN Surgical, Diagnostics) that is predominantly women's-health; figures fetched from the fiscal Q2 2025 release.
Financial evidence

Insufficient public evidence

No compatible fiscal period has been accepted.

Limitation: No reusable official filing evidence has been ingested for this issuer yet; financial metrics remain unavailable rather than estimated, and deeper primary research is pending.

Risks

Material risks and break conditions

Material risks

  • Reimbursement is discretionary and employer/state-budget-dependent; mandate momentum can stall (e.g., a governor vetoed a broader Medicaid fertility mandate) and Medicaid coverage remains rare (only ~3 states).
  • Customer-acquisition costs in direct-to-consumer femtech and virtual care can overwhelm care economics - an explicit thesis-break condition and a real risk for private platforms.

Thesis-break conditions

  • Reimbursement remains weak: state fertility-mandate expansion stalls or retreats and Progyny covered-lives/client growth turns negative for two-plus consecutive quarters.
  • Care economics break: fertility-benefit or digital-platform gross margins compress materially, or Progyny's historically high client retention falls below ~95%, or private femtech marks down on CAC-driven losses.
Investability conclusion

Where the evidence lands

Identity is established; theme materiality is stated per the mapped theme assessment. This is a filing-backed research profile with deeper company-specific research pending, and is not a personalized recommendation.

Next diligence

  1. FY2025 10-K segment detail; ThinPrep/Aptima volumes and ASPs; Genius AI/3D mammography adoption and the breast-health capital replacement cycle.
Source ledger

Identity and evidence sources

Identity was verified against official issuer, filing, exchange, or regulator sources where available.

  1. SEC EDGAR company search — HologicSEC EDGAR · primary · published 2026-07-22 · accessed 2026-07-22